MarketInOut Stock Screener Log In | Sign Up

Adlai Nortye Group Ltd ADR

NASDAQ • Healthcare • Biotechnology • Quote as of 11/20/2026
Adlai Nortye Group Ltd ADR stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization550.6 mln
Float53.36 mln
Earnings Date08/13/2027

Piotroski F-Score

2 / 9
Weak

Relative Strength

9 / 100
Severely lagging

Debt / Equity

0.12
Very low leverage

Pre-Tax Margin

-125%
Severely loss-making

ROE

-31.54
Deeply negative

Altman Z-Score

-13.71
Deeply distressed

Business Description

Adlai Nortye Ltd. is a Cayman Islands-based company founded in 2004 that focuses on developing new cancer treatments across the United States and other markets. The company has several drugs in early-stage clinical trials, targeting a range of cancers including pancreatic, lung, colorectal, esophageal, and rectal cancer. Its pipeline includes treatments that work by helping the immune system recognize and attack tumors, as well as drugs that block specific proteins known to drive cancer growth.

Key Fundamentals

EPS-0.68
ROE-31.54
RPS0.45
ROIC-61.77
ROA-19.06
Interest Cover-16.99
EBITDA, mln-21.28
EV / EBITDA-13.94
EV / EBIT-13.94
Revenue, mln18.10
EV / Revenue16.39

Quote Details

Last 8.55
Change -0.51 (-5.63%)
Open 8.93
Volume 380,645
Turnover 3,254,515
Average Volume 241,833

Financial Ratios

Pre-Tax Profit Margin-125
Leverage Ratio1.16
Current Ratio9.55
Price / Book2.93
Price / Tangible Book2.93
Debt / Equity0.12
Price / Sales26.84

Financial Strength

Altman Z-Score-13.71
Piotroski F-Score 2 / 9
Short Ratio18.50
Short % of Float9.95

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -19.42% 6 / 100   
1 Month -19.19% 13 / 100   
2 Months -35.91% 9 / 100   
6 Months -28.27% 14 / 100   
1 Year 486% 100 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog